{"id":852137,"date":"2025-05-19T06:53:01","date_gmt":"2025-05-19T10:53:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses\/"},"modified":"2025-05-19T06:53:01","modified_gmt":"2025-05-19T10:53:01","slug":"pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses\/","title":{"rendered":"Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">ZUG, Switzerland, May  19, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=EOuFab4BDbJBEPTn8aVOLzTsgT12wRdTuf2dseiCiZrmk6Wq8yFnr40Jd9vQaWsnScMsy3GiAII0AUoKbjiIKQ==\" rel=\"nofollow\" target=\"_blank\">Pharvaris<\/a> (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at three upcoming congresses: the 14<sup>th<\/sup> C1-Inhibitor Deficiency and Angioedema Workshop, to be held from May 29-June 1, 2025, in Budapest; the 2025 Eastern Allergy Conference (EAC), to be held from May 29-June 1, 2025, in Palm Beach, Fl.; and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, to be held from June 13-16, 2025, in Glasgow.<\/p>\n<p>Details of the presentations are as follows:<br \/><strong>C1-Inhibitor Deficiency and Angioedema Workshop<\/strong>, Budapest, May 29-June 1, 2025.<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Title: <\/strong>Clinical Validation of a Novel Biomarker Assay to Characterize Bradykinin-Mediated Angioedema in Prospective and Biobank Plasma Samples<br \/><strong>Presenter: <\/strong>Evangelia Pardali, Ph.D.<br \/><strong>Format: <\/strong>Oral Presentation, O-02<br \/><strong>Date, time: <\/strong>Friday, May 30, 8:45-9:00 CEST (2:45-3:00 a.m. ET)<\/li>\n<li>\n          <strong>Title: <\/strong>Long-Term Prophylactic Treatment With Oral Deucrictibant Improves Health-Related Quality of Life and Disease Control in Participants With Hereditary Angioedema: CHAPTER-1 Open-Label Extension Study<br \/><strong>Presenter: <\/strong>Markus Magerl, M.D.<br \/><strong>Format: <\/strong>Poster Presentation, P-19<br \/><strong>Date, time: <\/strong>Friday, May 30, 15:45-17:30 CEST (9:45-11:30 a.m. ET)<\/li>\n<li>\n          <strong>Title: <\/strong>Sustained Therapeutic Exposure with Once-Daily Oral Deucrictibant XR Tablet for Prophylaxis of Hereditary Angioedema Attacks: Results of a Pharmacokinetics Study in Healthy Volunteers<br \/><strong>Presenter: <\/strong>Zhi-Yi Zhang, Ph.D. <br \/><strong>Format: <\/strong>Poster Presentation, P-20<br \/><strong>Date, time:<\/strong> Friday, May 30, 15:45-17:30 CEST (9:45-11:30 a.m. ET)<\/li>\n<li>\n          <strong>Title:<\/strong> Acquired Angioedema Due to C1-Inhibitor Deficiency: Patient Experience and Assessment of Patient-Reported Outcome Measures<br \/><strong>Presenter:<\/strong> Andrea Zanichelli, M.D., Ph.D.<br \/><strong>Format: <\/strong>Poster Presentation, P-17<br \/><strong>Date, time:<\/strong> Friday, May 30, 15:45-17:30 CEST (9:45-11:30 a.m. ET)<\/li>\n<li>\n          <strong>Title: <\/strong>Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study<br \/><strong>Presenter:<\/strong> Emel Ayg\u00f6ren-P\u00fcrs\u00fcn, M.D.<br \/><strong>Format: <\/strong>Oral Presentation, O-33<br \/><strong>Date, time:<\/strong> Saturday, May 31, 15:30-15:45 CEST (9:30-9:45 a.m. ET)<\/li>\n<li>\n          <strong>Title: <\/strong>Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study<br \/><strong>Presenter: <\/strong>Marc A. Riedl, M.D., M.S.<br \/><strong>Format: <\/strong>Oral Presentation, O-34<br \/><strong>Date, time:<\/strong> Saturday, May 31, 15:45-16:00 CEST (9:45-10:00 a.m. ET)<\/li>\n<li>\n          <strong>Title:<\/strong> Durability Of Response to a Single Dose of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks<br \/><strong>Presenter: <\/strong>Anna Valerieva, M.D., Ph.D.<br \/><strong>Format: <\/strong>Poster Presentation, P-56<br \/><strong>Date, time:<\/strong> Saturday, May 31, 16:45-17:45 CEST (10:45-11:45 a.m. ET)<\/li>\n<li>\n          <strong>Title: <\/strong>CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks<br \/><strong>Presenter:<\/strong> Andrea Zanichelli, M.D., Ph.D.<br \/><strong>Format: <\/strong>Poster Presentation, P-42<br \/><strong>Date, time: <\/strong>Saturday, May 31, 16:45-17:45 CEST (10:45-11:45 a.m. ET)<\/li>\n<li>\n          <strong>Title:<\/strong> Safety and Efficacy of Oral Deucrictibant for Treatment of Upper Airway and Laryngeal Hereditary Angioedema Attacks: Results from the RAPIDe-2 Extension Study<br \/><strong>Presenter: <\/strong>Ram\u00f3n Lleonart, M.D.<br \/><strong>Format: <\/strong>Poster Presentation, P-55<br \/><strong>Date, time:<\/strong> Saturday, May 31, 16:15-17:45 CEST (10:15-11:45 a.m. ET)<\/li>\n<li>\n          <strong>Title:<\/strong> Epidemiology of Bradykinin-Mediated Angioedema in the European Population<br \/><strong>Presenter: <\/strong>Emel Ayg\u00f6ren-P\u00fcrs\u00fcn, M.D.<br \/><strong>Format: <\/strong>Poster Presentation, P-30<br \/><strong>Date, time:<\/strong> Saturday, May 31, 16:15-17:45 CEST (10:15-11:45 a.m. ET)<\/p>\n<\/li>\n<\/ul>\n<p>\n        <strong>2025 Eastern Allergy Conference<\/strong>, Palm Beach, Fl., May 29-June 1, 2025.<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Title: <\/strong>Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study<br \/><strong>Presenter: <\/strong>John Anderson, M.D.<br \/><strong>Format: <\/strong>Poster Presentation<br \/><strong>Date, time: <\/strong>Friday, May 30, 9:45-11:00 a.m. ET<\/li>\n<li>\n          <strong>Title: <\/strong>Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study<br \/><strong>Presenter: <\/strong>John Anderson, M.D.<br \/><strong>Format: <\/strong>Poster Presentation<br \/><strong>Date, time:<\/strong> Friday, May 30, 9:45-11:00 a.m. ET<\/p>\n<\/li>\n<\/ul>\n<p>\n        <strong>EAACI Congress 2025<\/strong>, Glasgow, June 13-16, 2025.<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Title: <\/strong>Clinical Validation of a Novel Kinin Biomarker Assay for Characterization of Bradykinin-Mediated Pathologies in U.S. Subjects with Hereditary Angioedema<br \/><strong>Presenter: <\/strong>Evangelia Pardali, Ph.D.<br \/><strong>Format: <\/strong>Flash Talk (e-Poster), Abstract #000949, FT03<br \/><strong>Date, time: <\/strong>Friday, June 13, 13:15-14:45 BST (8:15-9:45 a.m. ET)<\/li>\n<li>\n          <strong>Title: <\/strong>Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Results of the CHAPTER-1 Open-Label Extension Study<br \/><strong>Presenter: <\/strong>Emel Ayg\u00f6ren-P\u00fcrs\u00fcn, M.D.<br \/><strong>Format: <\/strong>Thematic Poster Session (e-Poster and Poster Session) Abstract #000070<br \/><strong>Date, time:<\/strong> Saturday, June 14, 12:00-13:00 BST (7:00-8:00 a.m. ET)<\/li>\n<li>\n          <strong>Title: <\/strong>Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study<br \/><strong>Presenter: <\/strong>Henriette Farkas, M.D., Ph.D., D.Sc.<br \/><strong>Format: <\/strong>Thematic Poster Session (e-Poster and Poster Session), Abstract #000069<br \/><strong>Date, time: <\/strong>Saturday, June 14, 12:00-13:00 BST (7:00-8:00 a.m. ET)<\/li>\n<li>\n          <strong>Title: <\/strong>Development of a Conceptual Model Supporting a Clinical Outcome Assessment Strategy for Acquired Angioedema due to C1 Inhibitor Deficiency<br \/><strong>Presenter: <\/strong>Andrea Zanichelli, M.D., Ph.D.<br \/><strong>Format: <\/strong>Thematic Poster Session (e-Poster and Poster Session), Abstract #000331<br \/><strong>Date, time:<\/strong> Sunday, June 15, 12:45-13:45 BST (7:45-8:45 a.m. ET)<\/li>\n<li>\n          <strong>Title: <\/strong>Safety and Efficacy of Oral Deucrictibant for Treatment of Upper Airway and Laryngeal Hereditary Angioedema Attacks: Results from the RAPIDe-2 Extension Study<br \/><strong>Presenter: <\/strong>Anna Valerieva, M.D., Ph.D.<br \/><strong>Format: <\/strong>Flash Talk (e-Poster), Abstract #000076, FT16<br \/><strong>Date, time:<\/strong> Sunday, June 15, 14:00-15:30 BST (9:00-10:30 a.m. ET)<\/li>\n<li>\n          <strong>Title: <\/strong>CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks<br \/><strong>Presenter: <\/strong>William Lumry, M.D.<br \/><strong>Format: <\/strong>Flash Talk (e-Poster), Abstract #000068, FT16<br \/><strong>Date, time:<\/strong> Sunday, June 15, 14:00-15:30 BST (9:00-10:30 a.m. ET)<\/li>\n<li>\n          <strong>Title: <\/strong>Long-Term Prophylactic Treatment with Oral Deucrictibant Improves Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema in the CHAPTER-1 Open-Label Extension Study<br \/><strong>Presenter: <\/strong>Markus Magerl, M.D.<br \/><strong>Format: <\/strong>Flash Talk (e-Poster), Abstract #000075, FT16<br \/><strong>Date, time:<\/strong> Sunday, June 15, 14:00-15:30 BST (9:00-10:30 a.m. ET)<\/li>\n<li>\n          <strong>Title: <\/strong>Health-Related Quality of Life and Clinical Characteristics in People Living with Hereditary Angioedema Prescribed Long Term Prophylaxis Alone and On-Demand Treatment Alone<br \/><strong>Presenter: <\/strong>Laurence Bouillet, M.D., Ph.D.<br \/><strong>Format: <\/strong>Oral Presentation, Abstract #000044, OAS18<br \/><strong>Date, time:<\/strong> Sunday, June 15, 15:45-17:15 BST (10:45 a.m.-12:15 p.m. ET)<\/li>\n<\/ul>\n<p>The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZWMWkJjiorxYfAmyUjRKRjqD-N-rbbQx9WY48pJYM5Z5HDSBlX52zKICANnRcJbEyBNgnwbyXQA2tfahJRUZ7sv5CRXjuTmzF_B5k7ZvQZMN08y8Thh8FjzDMV8i38xSmYti_-7wUNy6mN83rmfqI6lYoknkf-XpDgWqgNtr0nKE2OAIv1JDhkCuDJyUTy-z39IzLluXsyfSeDLHmAyQb4wLzc2r7vYNrtyghs8sNt-DaIn7f0CJxCq5rAfJfaAWFJExtpZy3Jg2dLAjJkLtkFCWPu045UboXgtkhwhLUP3HYA-zE_65fBkCa6Y8KK-U_DxTOCsFsUWftj9MpA5nqfip7eb9IC5ie5nj_zSUaAphkH5fLeH1LV0CcAJP_8cplgQ8vVpCa3G2y5pCfCW631Ke3s0UVSwCsJu69ZXXypk=\" rel=\"nofollow\" target=\"_blank\">https:\/\/ir.pharvaris.com\/news-events\/events-presentations<\/a>.<\/p>\n<p>\n        <strong>About Pharvaris<\/strong><br \/>\n        <br \/>Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to potentially address all types of bradykinin-mediated angioedema. Pharvaris intends to provide injectable-like efficacy\u2122 and placebo-like tolerability with the convenience of an oral therapy to prevent and treat bradykinin-mediated angioedema attacks. With positive data in both Phase 2 prophylaxis and on-demand studies in HAE, Pharvaris is currently evaluating the efficacy and safety of deucrictibant in a pivotal Phase 3 study for the prevention of HAE attacks (CHAPTER-3) and a pivotal Phase 3 study for the on-demand treatment of HAE attacks (RAPIDe-3). For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZWMWkJjiorxYfAmyUjRKRognkCryxIlMKiNUdd9p0DVv-0fjh4kbRrvtYfDg2LiblIcoCRgRlYDvslAW19cYAuppPPFnNXcaQqn05qutY5s=\" rel=\"nofollow\" target=\"_blank\">https:\/\/pharvaris.com\/<\/a>.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1Mzg3MSM2OTQ4Mzg0IzIyMDU5NDc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MjU3ZmYyNzEtZjEwMS00M2M4LWJjMDAtNDI2OGJhMzRiNTg0LTEyMTc1MDAtMjAyNS0wNS0xOS1lbg==\/tiny\/Pharvaris-N-V-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Contact\r\nMaggie Beller\r\nExecutive Director, Head of Corporate and Investor Communications\r\nmaggie.beller@pharvaris.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ZUG, Switzerland, May 19, 2025 (GLOBE NEWSWIRE) &#8212; Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at three upcoming congresses: the 14th C1-Inhibitor Deficiency and Angioedema Workshop, to be held from May 29-June 1, 2025, in Budapest; the 2025 Eastern Allergy Conference (EAC), to be held from May 29-June 1, 2025, in Palm Beach, Fl.; and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, to be held from June 13-16, 2025, in Glasgow. Details of the presentations are &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-852137","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ZUG, Switzerland, May 19, 2025 (GLOBE NEWSWIRE) &#8212; Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at three upcoming congresses: the 14th C1-Inhibitor Deficiency and Angioedema Workshop, to be held from May 29-June 1, 2025, in Budapest; the 2025 Eastern Allergy Conference (EAC), to be held from May 29-June 1, 2025, in Palm Beach, Fl.; and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, to be held from June 13-16, 2025, in Glasgow. Details of the presentations are &hellip; Continue reading &quot;Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-19T10:53:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1Mzg3MSM2OTQ4Mzg0IzIyMDU5NDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses\",\"datePublished\":\"2025-05-19T10:53:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses\\\/\"},\"wordCount\":1125,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1Mzg3MSM2OTQ4Mzg0IzIyMDU5NDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses\\\/\",\"name\":\"Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1Mzg3MSM2OTQ4Mzg0IzIyMDU5NDc=\",\"datePublished\":\"2025-05-19T10:53:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1Mzg3MSM2OTQ4Mzg0IzIyMDU5NDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1Mzg3MSM2OTQ4Mzg0IzIyMDU5NDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses\/","og_locale":"en_US","og_type":"article","og_title":"Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses - Market Newsdesk","og_description":"ZUG, Switzerland, May 19, 2025 (GLOBE NEWSWIRE) &#8212; Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the acceptance of abstracts for presentation at three upcoming congresses: the 14th C1-Inhibitor Deficiency and Angioedema Workshop, to be held from May 29-June 1, 2025, in Budapest; the 2025 Eastern Allergy Conference (EAC), to be held from May 29-June 1, 2025, in Palm Beach, Fl.; and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, to be held from June 13-16, 2025, in Glasgow. Details of the presentations are &hellip; Continue reading \"Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-19T10:53:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1Mzg3MSM2OTQ4Mzg0IzIyMDU5NDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses","datePublished":"2025-05-19T10:53:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses\/"},"wordCount":1125,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1Mzg3MSM2OTQ4Mzg0IzIyMDU5NDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses\/","name":"Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1Mzg3MSM2OTQ4Mzg0IzIyMDU5NDc=","datePublished":"2025-05-19T10:53:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1Mzg3MSM2OTQ4Mzg0IzIyMDU5NDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1Mzg3MSM2OTQ4Mzg0IzIyMDU5NDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pharvaris-to-present-deucrictibant-clinical-data-and-exploratory-biomarker-data-at-upcoming-congresses\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pharvaris to Present Deucrictibant Clinical Data and Exploratory Biomarker Data at Upcoming Congresses"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/852137","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=852137"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/852137\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=852137"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=852137"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=852137"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}